Company Encyclopedia
View More
name
Matinas Biopharma
MTNB.US
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company’s LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for the treatment of aspergillosis and cryptococcosis, as well as prevention of invasive fungal infections in patients due to immunosuppressive therapy. It offers MAT2501, an orally administered formulation of amikacin.
1.946 T
MTNB.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Matinas Biopharma Holdings Inc - CFO Keith Kucinski Resigns Effective January 17, 2026 - SEC Filing

    Matinas BioPharma Holdings Inc :MATINAS BIOPHARMA HOLDINGS INC - CFO KEITH KUCINSKI RESIGNS EFFECTIVE JANUARY 17, 2026 - SEC FILING

    Reuters·
    US
    MTNB
    +0.09%
    Reuters·
    US
    MTNB
    +0.09%

    Matinas BioPharma CFO Keith Kucinski Resigns

    Matinas BioPharma Holdings Inc. announced the resignation of CFO Keith Kucinski, effective January 17, 2026, to pursue other opportunities. The resignation is not due to any disagreement with the company. This information was published via EDGAR by Matinas BioPharma and is for informational purposes only.

    Reuters·
    US
    MTNB
    +0.09%
    Reuters·
    US
    MTNB
    +0.09%

    Pre-market hot trades in US stocks: Matinas Biopharma up 10.74% in pre-market; Jyong Biotech up 9.70% in pre-market

    Matinas Biopharma pre-market rose 10.74%; Jyong Biotech pre-market rose 9.70%; Sonder pre-market rose 110.53%; Mobile-Health Network Solutions pre-market rose 74.11%; PACS pre-market rose 50.03%

    Tracking Unusual Activity·
    US
    MTNB
    +0.09%
    US
    MENS
    -0.21%
    Tracking Unusual Activity·
    US
    MTNB
    +0.09%
    US
    MENS
    -0.21%

    Matinas Biopharma | 10-Q: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    MTNB
    +0.09%
    LB filings·
    US
    MTNB
    +0.09%

    Matinas BioPharma Holdings, Inc. (MTNB) Restructures Amid Challenges, Focuses on Oral Antifungal MAT2203

    Matinas BioPharma Holdings, Inc. (MTNB) is undergoing restructuring to address challenges while focusing on its lead oral antifungal candidate, MAT2203. The company, a clinical-stage biopharmaceutical firm, specializes in developing oral anti-infective therapies using its proprietary lipid nanocrystal (LNC) platform. It is highlighted as one of the top biotech penny stocks to consider for investment.

    MSN·
    US
    MTNB
    +0.09%
    MSN·
    US
    MTNB
    +0.09%
    © 2025 Longbridge｜Disclaimer